Lilly (LLY) announces analysis performed by Washington University School of Medicine in DIAN-TU Study showed solanezumab did not meet primary endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Lilly (LLY) announces analysis performed by Washington University School of Medicine in DIAN-TU Study showed solanezumab did not meet primary endpoint

Eli Lilly & Co. (LLY) & Incyte (INCY) Report Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib

February 12, 2020 5:54 AM EST

Eli Lilly (NYSE: LLY) and Company and Incyte (NASDAQ: INCY) announced that baricitinib met the primary endpoint in BREEZE-AD5, an investigational Phase 3, randomized, placebo-controlled study evaluating the safety and efficacy of baricitinib for the treatment of adult patients with moderate- to severe atopic dermatitis (AD). The primary endpoint was defined by the proportion of patients achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) at Week 16.

Atopic dermatitis is chronic skin condition which affects approximately one to three percent of... More

Mizuho Securities Reiterates Neutral Rating on Eli Lilly (LLY)

February 11, 2020 7:19 AM EST

Mizuho Securities analyst Vamil Divan reiterated a Neutral rating and $148.00 price target on Eli Lilly (NYSE: LLY) following the company's announcement that the DIAN-TU study did not meet the primary endpoint of showing an improvement for the drug over placebo. Divan believes some... More